查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球恶性间皮瘤治疗药物市场 - 2023-2030年
市场调查报告书
商品编码
1289781

全球恶性间皮瘤治疗药物市场 - 2023-2030年

Global Malignant Mesothelioma Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球恶性间皮瘤治疗剂市场在2022年达到2.593亿美元，预计到2030年将见证有利可图的增长，达到5.127亿美元。在预测期内（2023-2030年），全球恶性间皮瘤治疗药物预计将呈现9.1%的复合增长率。

主要的行业驱动因素，包括恶性间皮瘤实例的增加，癌症治疗意识的提高，石棉在各种行业中的使用不断扩大，以及不断扩大的技术突破，预计将支持市场扩张。

在预计的时期内，全球恶性间皮瘤治疗剂市场预计将受益于复杂的治疗方法的出现。此外，全球恶性间皮瘤治疗剂市场可能会受到各种产品和行业中的石棉的推动，这是形成间皮瘤的一个关键原因。

市场动态

在早期阶段诊断和治疗疾病的意识运动的增加将推动市场增长

恶性间皮瘤在世界范围内变得越来越普遍，因此有必要增加宣传活动，以便在早期阶段诊断和治疗该疾病。许多团体正在提高对这一疾病的认识，并建议接触石棉的雇员经常接受恶性间皮瘤的筛查，这有助于防止该疾病发展到晚期阶段。这种认识的提高预计将对市场的整体增长产生积极的影响。

此外，烟草和吸烟消费的增加推动了恶性间皮瘤治疗剂市场的发展。全球恶性间皮瘤市场的大多数公司正在与各组织合作，探索结合众多药物对恶性间皮瘤的影响。由于技术专利的稀缺性，许多公司正在进行以各种组合药物为重点的临床研究。

恶性间皮瘤的漫长潜伏期可能会阻碍市场的增长

恶性间皮瘤潜伏期长，在早期阶段缺乏疾病特异性生物标志物，以及用于癌症治疗的创新设备的开发和批准，可能会在整个预测期内减缓恶性间皮瘤治疗市场的增长。

COVID-19影响分析

全球恶性间皮瘤治疗剂市场受益于COVID-19的爆发。关于COVID-19的情况，几个细分市场的药物需求量增加了。该行业的制药企业大大改善了供应链管理，提高了研发技能，增加了生产管理和质量控制投资。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按药物类别简述
  • 按给药途径分析
  • 按终端用户分类

第四章：动态变化

  • 影响因素
    • 驱动因素
    • 限制因素
      • 恶性间皮瘤的潜伏期长
    • 机会
      • 越来越多地采用先进技术
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按药物类型

  • 培美曲塞
  • 顺铂
  • 卡铂
  • 吉西他滨
  • 长春瑞滨
  • 其他

第8章：按给药途径分类

  • 口服
  • 肠外

第9章：按给药途径分类

  • 医院
  • 癌症中心
  • 其他

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Dr. Reddy's Laboratories,
  • Wellona Pharmaceuticals
  • Bristol-Myers Squibb
  • Novocure
  • Eli Lilly and Company
  • Merck
  • Manus Aktteva Biopharma LLP
  • Pfizer
  • Ono Pharmaceuticals

第十三章 ：附录

简介目录
Product Code: PH5147

Market Overview

The Global Malignant Mesothelioma Therapeutics Market reached US$ 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 512.7 million by 2030. The global malignant mesothelioma therapeutics is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

The main industry drivers, including the rise in malignant mesothelioma instances, rising cancer treatment awareness, expanding use of asbestos in a variety of industries, and expanding technical breakthroughs, are anticipated to support market expansion.

Over the projected period, the global malignant mesothelioma therapeutics market is expected to benefit from the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.

Market Dynamics

Increased Awareness Campaigns to Diagnose and Treat the Disease at an Earlier Stage will Drive the Market Growth

Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending that asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.

Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.

The Long Latency Period For Malignant Mesothelioma Is Likely To Hamper The Market Growth

A long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.

COVID-19 Impact Analysis

The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. About the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.

Segment Analysis

Pemetrexed Drug in Drug Class Segment will Dominate in the Market by Capturing 39.1% During the Forecast Period

The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibodies, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs.

These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.

Geographical Analysis

North America is the Dominating Region During the Forecast Period

In 2022, the United States is a key participant in this region, accounting for approximately 39.2% of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market size in North America is growing faster than in other areas. Advanced healthcare infrastructure is also expected to drive and contribute to the growth of the malignant mesothelioma therapeutics market in North America.

Competitive Landscape

The major global players include: Dr. Reddy's Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.

  • Why Purchase the Report?
  • To visualize the global malignant mesothelioma therapeutics market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End user

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers

Increased awareness campaigns to diagnose and treat the disease at an earlier stage

    • 4.1.2. Restraints
      • 4.1.2.1. The long latency period for malignant mesothelioma
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing adoption of advanced technologies
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Pemetrexed
  • 7.2. Cisplatin
  • 7.3. Carboplatin
  • 7.4. Gemcitabine
  • 7.5. Vinorelbine
  • 7.6. Others

8. By Route of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. By Route of Administration

  • 9.1 Hospitals
  • 9.2 Cancer Centers
  • 9.3 Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%) By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Use
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Dr. Reddy's Laboratories,
  • 12.2. Wellona Pharmaceuticals
  • 12.3. Bristol-Myers Squibb
  • 12.4. Novocure
  • 12.5. Eli Lilly and Company
  • 12.6. Merck
  • 12.7. Manus Aktteva Biopharma LLP
  • 12.8. Pfizer
  • 12.9. Ono Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us